Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar
ataxia, essential tremor and schizophrenia.
At the 2019 American Academy of Neurology Annual Meeting, the Company presented preclinical data on AMT-150 for the treatment of Spinocerebellar
Ataxia Type 3.
FDA Approves IND For Phase 2 Clinical Trial Spinocerebellar
Ataxia (July 2018)
They identified down regulation of the microRNA miR-29 as a common event in patients and animal models of several neurodegenerative disorders including Alzheimers's disease, Huntington's disease and spinocerebellar
announced last July that the FDA had raised no objections to the company's Investigational New Drag (IND) application for a Phase 2 clinical trial in polyglutamine spinocerebellar
ataxia (PolyQ SCA) conducted at clinical sites in the U.S.
It may be secondary to neuropathy, demyelination of spinocerebellar
tracts or direct damage to cerebellum.
The CAP offers proficiency testing for a subset of spinocerebellar
ataxia (SCA) assays twice per year.
The major differential diagnosis of CANVAS are spinocerebellar
ataxia type 3 (SCA3), Friedreich ataxia (FRDA), multiple system atrophy of cerebellar type, and Wernicke encephalopathy .
All patients were elderly and suffered from cerebrovascular disease, degenerative orthopedic disease, Parkinson's disease, spinocerebellar
degeneration, diabetic neuropathy, spinal cord injury, or disuse syndrome.
He noted that the work presents potential benefits beyond spinal cord injury therapies since the NSCs can be used in modeling and drug screening for disorders that also involve spinal cord dysfunction, such as amyotrophic lateral sclerosis, progressive muscular atrophy, hereditary spastic paraplegia and spinocerebellar
ataxia, a group of genetic disorders characterized by progressive discoordination of gait, hands and eye movement.
Disorders such as Huntington's disease (HD), spinocerebellar
ataxia (SCA) types 1, 2, 3, 6, 7, 8, and 17, dentatorubral-pallidoluysian atrophy, and spinal and bulbar muscular atrophy are typically associated with a protein gain-of-function mechanism (53).